Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective vigilantly but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my last few shares. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set out what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire interview that I came away with an inadequate opinion of the business.

Irony of irony, the bad impression of mine of the business has grown steadily, however, the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the technology and connected intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) along with the very first new drug application approval ($five million), and even royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and numerous indications, it’s this single treatment and a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on its website (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the really beginning of my interest in this business. Judging by way of the multiples of a huge number of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or even some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *